This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xing, D. Articles by Orsulic, S. Search for Related Content PubMed PubMed Citation Articles by Xing, D. Articles by Orsulic, S.

A Mouse Model for the Molecular Characterization of Brca1-Associated Ovarian Carcinoma

¹ Molecular Pathology Unit and Center for Cancer Research, Massachusetts General Hospital, Charlestown, Massachusetts and ² Department of Pathology, Harvard Medical School, Boston, Massachusetts

Requests for reprints: Sandra Orsulic, Molecular Pathology Unit and Center for Cancer Research, Massachusetts General Hospital, 13th Street, Building 149, CNY7, Charlestown, MA 02129. Phone: 617-726-5674; Fax: 617-726-5684; E-mail: sorsulic{at}partners.org.

Little is known about the mechanisms that underlie Brca1-associated ovarian tumorigenesis, mainly due to the lack of an appropriate experimental model. We developed genetically defined primary mouse ovarian surface epithelial (OSE) cell lines in which the loss of functional Brca1 and p53 recapitulates the events that are thought to occur in early ovarian cancer development in patients with Brca1 mutations. This system allows for the introduction of additional oncogenes that are thought to cooperate with the loss of Brca1 and p53 to induce tumorigenesis. We showed that Myc is sufficient to induce transformation of ovarian cells that are deficient for both Brca1 and p53 but not sufficient for the transformation of cells that are deficient for either Brca1 or p53. The transformed Brca1-deficient OSE cells display an increased number of centrosomes, acquire complex chromosome aberrations, and lack Rad51 nuclear foci in the presence of DNA-damaging agents, such as mitomycin C and cisplatin. Immunocompetent mice injected with transformed OSE cells develop tumors that resemble human metastatic serous ovarian carcinoma, the most common type of ovarian cancer in women. Consistent with the reported platinum chemosensitivity in patients with Brca1-associated ovarian cancer, the Brca1-deficient OSE cells have increased sensitivity to the DNA-damaging agent cisplatin, whereas sensitivity to the microtubule poison paclitaxel is similar between Brca1 wild-type and Brca1-deficient cells. The Brca1 wild-type and Brca1-deficient mouse ovarian tumors and cell lines provide a new experimental system for the evaluation of therapies that target the Brca1 pathway. (Cancer Res 2006; 66(18): 8949-53)

This article has been cited by other articles:

				J. I. Weberpals, K. V. Clark-Knowles, and B. C. Vanderhyden Sporadic Epithelial Ovarian Cancer: Clinical Relevance of BRCA1 Inhibition in the DNA Damage and Repair Pathway J. Clin. Oncol., July 1, 2008; 26(19): 3259 - 3267. [Abstract] [Full Text] [PDF]

				J. E. Quinn, C. R. James, G. E. Stewart, J. M. Mulligan, P. White, G. K.F. Chang, P. B. Mullan, P. G. Johnston, R. H. Wilson, and D. P. Harkin BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy Clin. Cancer Res., December 15, 2007; 13(24): 7413 - 7420. [Abstract] [Full Text] [PDF]

				C. K. Donawho, Y. Luo, Y. Luo, T. D. Penning, J. L. Bauch, J. J. Bouska, V. D. Bontcheva-Diaz, B. F. Cox, T. L. DeWeese, L. E. Dillehay, et al. ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models Clin. Cancer Res., May 1, 2007; 13(9): 2728 - 2737. [Abstract] [Full Text] [PDF]

				J. J. Schumacher, R. P.M. Dings, J. Cosin, I. V. Subramanian, N. Auersperg, and S. Ramakrishnan Modulation of Angiogenic Phenotype Alters Tumorigenicity in Rat Ovarian Epithelial Cells Cancer Res., April 15, 2007; 67(8): 3683 - 3690. [Abstract] [Full Text] [PDF]